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Fisher’s group identified melanoma differentiation-associated protein-7 (MDA-7) upon discovery of cell 
surface receptor MDA-7 renamed Interleukin 24 (IL24).It has three N-glycosylation sites. IL24 signals 
through receptors. Binding of IL24 to receptors leads to the activation of STAT-3 and STAT-1. IL 24 
induces the secretion of high level of Interferon Gamma  (IFN-γ) ,IL6 and tumor necrosis factor alpha 
(TNF-α) and low levels of IL1,IL12 and granulocyte macrophage colony stimulating factor (GM-CSF) 
from human peripheral blood mononuclear cells(PBMC). IL24 has growth suppressive properties in a 
wide variety of human cancer cell lines without inducing harmful effects in normal cells. This review is 
focused on the role of IL 24 on tumor cell biology and its potential therapeutic applications. 
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INTRODUCTION 
 
In the mid-1990s, Paul Fisher’s group at 
Colombia University identified a gene by 
substraction hybridization, MDA-7 (melanoma 
differentiation-associated protein-7). In 2002 
MDA-7 was renamed interleukin 24 (IL24) 
upon discovery of cell surface receptors [1]. 
The molecular weight of human IL24 is 
23.8Kd. The molecular weight of 
unglycosylated IL24 is 18 Kd (Table 1), while 
secreted glycosylated IL24 has a molecular 
weight of 35 Kd [2]. IL24 contains three N-
glycosylation sites (N85IT, N99VS, and 
N126RT). N-glycosylation plays a critical role 
in modulating immunological and biological 
functions of glycoprotein [3].  IL24 genomic 
locus has been mapped to chromosome Iq32 
with an IL10 related gene cluster containing 
four genes including IL10, IL19 and IL20. IL24 
has been designated as member of 
interleukin 10 family of cytokines. This family 
includes IL10, IL19, IL20, IL22, IL24 and IL26 
[4].   IL24 signals through its corresponding 
heterodimeric receptors consisting of  
IL20R1/IL20R2 and IL22R1/IL20R2.The R1 
and R2 are receptors subunits, R1 contains a 
long cytoplasmic tail and R2 contain a short 
cytoplasmic tail. IL24 has equal affinity for 
both receptor complexes. Binding of IL24 to 
both receptors leads to the activation of 
STAT-3 and to a lesser extant STAT-1 [5].  
IL24 receptors are expressed on human 
neutrophils, CD4⁺  T- cells, CD8⁺  T- cells 
and murine neutrophils [3]. Expression of 
IL24 receptor depends on restrictive 
expression of IL20R2 in certain non-
haemopoietic tissues including skin, lungs, 
testis and ovary [6]. Over expression of IL24 
receptor has been reported in the epidermis 
of psoriatic skin [7]. The expression of IL24 is 
inversely correlated with melanoma 
progression. Analysis of IL10 family member 
mRNA has revealed that IL24 mRNA is 
expressed in monocytes and T-cells [8]. IL24 
over expressed in colorectal cancers with 
microsatellite instability [9]. IL24 mediates its 
biological functions through autocrine and 
paracrine actions. IL 24 induces the secretion 
of high level of Interferon Gamma  (IFN-γ) , 
IL6 and tumor necrosis factor alpha (TNF-α) 
and low level of IL1,IL12 and granulocyte 
macrophage colony stimulating factor (GM-
CSF) from human peripheral blood 
mononuclear cells (PBMC) [3].  
 
Table 1: Characteristics of Interleukin 24 [2] 
 
Parameter Homodimer and monomer 
Size (mol wt) 
 
 
23.8 kd (predicted size of 
unprocessed precursor) 
18 kd (unglycosylated mature 
protein) 
35 kd (observed size of 
secreted IL-24, glycosylated) 
Receptors IL20R1/IL-20R2 and IL-
22R1/IL-20R2 
Cell sources Melanocytes, T 
cells,monocytes 
Cell targets Cancer cells 





Melanoma differentiation associated gene-
7/IL24 and melanoma 
 
Melanoma represents an aggressive cancer 
that most frequently metastasizes the lymph 
node region and to distant sites as the 
disease progress. In the United States the 
incidence of melanoma is increasing at a 
faster rate than any other cancer [10]. 
Surgery is an option for treating metastases 
as chemotherapy and radiotherapy do not 
achieve cure in majority of the patients and 
less than 5% of melanoma patients with 
systemic metastases survive 5 years or 
more[10]. Treatment with inclusion of a high 
level of Interferon alpha has shown significant 
increase in patient life time but not act 
towards the cure [11]. The metastases 
treatment focus on expression of skin cell 
protein as IL24 mRNA and protein are 
expressed in melanocytes and the only skin 
cell expressing IL24 protein constitutively 
[12]. Gupta et al [10] reported the expression 
of IL24 during melanoma progression. The 
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immune-histochemical analysis of IL24 
expression during tissue section of 
melanoma indicated abundant expression of 
IL24 protein in human nevi and in primary 
melanoma tumors.IL24 has growth 
suppressive properties in wide variety of 
human cancer cell lines without inducing 
harmful effects in normal cells [10]. 
 
Apoptosis Inducing Properties of IL24 
 
IL24 has growth inhibiting and apoptosis 
inducing properties in human tumors [13]. 
IL24 role in inducing apoptosis has been 
extensively studied since it was identified. 
The exact mechanism for this protein to act 
as a tumor suppressor is still unknown.  The 
secreted intracellular IL24 is able to induce 
apoptosis and inhibit tumor cell invasion [13]. 
The apoptosis inducing properties of IL24 
was first tested using replication incompetent 
adenoviral vector (Ad.IL24) in breast cancer 
cell lines (Table 2). Ad.IL24 inhibited growth 
and decreased the survival of the tumor cells 
invitro and invivo without having the same 
effects on normal cells [4]. This apoptosis 
inducing ability of Ad.IL24 was demonstrated 
to be independent of the p53 or retinobla-  
 
Table 2: Summary of activities of Ad-mda7 and 
MDA-7 [6] 
 
Function /activity Ad-mda7 MDA-7 
Normal cell cytotoxicity     - -     - - 
Tumor cell cytotoxicity    + +    + + 
STAT3 activation    + +    + + 
Cytokine induction    + +    + + 
Anti-angiogenesis    + +    + + 
 
stoma (RB) tumor suppressor status of the 
target cells [14]. In prostate cancer cells free 
radicals are involved in IL24-induced 
apoptosis. Ad.IL24 selectively induces 
apoptosis by mitochondrial dysfunction and 
production of reactive oxygen species (ROS). 
IL24 increases the reactive oxygen species 
(ROS) production by 3-5 fold in cancer cells 
without having the same effect on normal 
cells [15]. A number of molecules involved in 
apoptotic signaling of IL24 in tumor cells have 
been identified. However identities of the 
critical molecules or signaling pathways for 
tumor cell apoptosis have not been 
assortmend [6, 16].   
 
Antitumor bystander activity of IL24 
 
The secreted form of IL24 has antitumor 
bystander activity. The exact mechanism of 
this activity is not yet known but it is thought 
to involve direct cytotoxicity, anti-angiogenic 
activity or it can be result of 
immunoregulatory activities [17].  IL24 is 
secreted from both normal and cancer cells 
after administration of Ad.IL24.These 
secreted proteins possess the antitumor 
bystander activity and are able to suppress 
growth, induce apoptosis and enhance 
radiation lethality in human cancer cells [18].  
 
Anti-angiogenic activity of IL24 
 
Angiogenesis is complex process that 
involves the formation of new blood vessels 
[19]. It is a fundamental event for tumor 
growth and metastasis. A number of 
angiogenesis inhibitors have been found and 
prove to be effective in pre clinical studies but 
very few of them have therapeutic effects in 
clinical trials [19].  IL24 secreted from 
transfected 293 cells inhibits endothelial cells 
differentiation and tumor growth. The 
inhibition of tumor growth was observed to be 
associated with reduced tumor 
vascularization. IL24 secreted from 
transfected 293 cells was detected to be 
more potent in inhibiting endothelial cell 
differentiation than endostatin. IL24 inhibits 
the endothelial cell migration [20]. 
 
Combination Therapy with IL24 
 
IL24 is able to efficiently induce apoptosis in 
a wide variety of human cancers except 
pancreatic and ovarian cancer [21]. IL24 
does not significantly alter growth or induce 
apoptosis in human pancreatic cancer cells 
due to the expression of oncogenic K-ras, 
which is a common genetic alteration in 
pancreatic cancers. This resistance for IL24 
can be overcome by combination treatment 
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with an antisense K-ras expression vector.  
Another way to overcome the problem is to 
use IL24 in combination with non-toxic doses 
of a chemical compound from the 
endoperoxide class [21]. It has been reported 
that IL24 is able to induce apoptosis in 
ovarian cancer cells with a low efficiency. 
Induction of apoptosis by IL24 can be 
enhanced by treating ovarian cells with 
ionizing radiation in combination with Ad.IL24 
[11]. 
 
IL24 and Mycobacterium tuberculosis 
 
Tuberculosis remains a global health 
problem. Multi-drug resistance tuberculosis 
(MDR)-TB, co infection with HIV and limited 
efficacy of BCG vaccine against TB in 
epidemic region of the word drew attention to 
the urgent need for potent anti-TB drug. IL24 
shows a protective effect against 
mycobacterium tuberculosis infection in vivo. 
IL24 acts as immunological regulatory 
molecule. IL24 receptors are expressed on 
CD8⁺ ⁺ T cells. IL24 activate human CD8  T 
cells, driving CD8⁺  T cells to produce Th1 
type cytokine IFN-γ and counteract TB [3]. 
 
IL24 in cancer therapy 
 
IL24 has clinical potential as an anti-cancer 
drug. It has many advantages compared to 
existing cancer therapeutics. These include 
activity against broad range of tumor types, 
lack of cytotoxicity against normal human 
cells, ability to induce antitumor bystander 
activity [18], ability to inhibit tumor 
angiogenesis and synergy with radiation, 
chemotherapy and monoclonal antibody 
therapies [8]. IL24 as fusion protein or with 
combination of viral vector confirm anticancer 




IL24 has progressed from a laboratory 
discovery to a potential therapeutic agent for 
Mycobacterium tuberculosis and cancer. 
Further investigations are clearly required to 
have a precise understanding of the 
mechanism of action of IL24 in cancer. 
Future research will be focused on the 
application of nanotechnology and stem cell 
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